OncoZenge AB
Developing a non-opioid lozenge for oral pain relief in cancer patients.
ONCOZ | ST
Overview
Corporate Details
- ISIN(s):
- SE0015504097
- LEI:
- 2549003980RBCR6NIF38
- Country:
- Sweden
- Address:
- Gustavslundsvagen 34, 5 tr, 167 51 Bromma
- Website:
- https://oncozenge.se/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
OncoZenge AB is a pharmaceutical company focused on developing innovative treatments for oral pain. Its lead candidate, BupiZenge™, is a novel lozenge formulation that utilizes the well-established local anesthetic bupivacaine to provide targeted, non-opioid pain relief. The primary indication is oral mucositis, a debilitating side effect of cancer radiotherapy and chemotherapy that represents a significant unmet medical need. By alleviating pain locally, BupiZenge™ aims to improve patients' quality of life, reduce the need for systemic opioids, and prevent hospitalizations. Having successfully completed Phase 1 and 2 trials and received regulatory guidance from the EMA and FDA, the company is preparing for Phase 3 studies and establishing commercial partnerships for market entry. The treatment also has potential applications for other oral pain conditions.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all OncoZenge AB filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Need More History? Access decades of standardized financials for OncoZenge AB via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-07 | Stian Kildal | Other | Buy | 20,439 | 85,026.24 SEK |
